A selective phosphodiesterase 4 (PDE4) inhibitor Zl-n-91 suppresses IL-17 production by human memory Th17 cells

International Immunopharmacology

Volumn 8, Issue 10, 2008, Pages 1408-1417

  Ma, Ruihong ^a   Yang, Bin yan ^a   Wu, Chang you ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Autoimmune diseases; Memory T cells; PDE4; Th17

Indexed keywords

INTERLEUKIN 17; PHOSPHODIESTERASE IV INHIBITOR; ZL N 91;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE ACTIVATION;

CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; HUMANS; IMMUNOLOGIC MEMORY; INTERLEUKIN-17; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; ROLIPRAM; T-LYMPHOCYTE SUBSETS;

EID: 50949132319     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2008.05.012     Document Type: Article

References (37)

1. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nature Rev Immunol 6 (2006) 329-333
2. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., and Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (2006) 677-688
3. Ouyang W., Kolls J.K., and Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28 4 (2008) 454-467
4. Yang X.O., Panopoulos A.D., Nurieva R., Chang S.H., Wang D., Watowich S.S., et al. STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282 (2007) 9358-9363
5. + T helper cells. Cell 126 (2006) 1121-1133
6. McGeachy M.J., and Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 28 4 (2008) 445-453
7. Li H., Chen J., Huang A., Stinson J., Heldens S., Foster J., et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci U S A. 97 (2000) 773-778
8. Moseley T.A., Haudenschild D.R., Rose L., and Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 14 (2003) 155-174
9. Harrington L.E., Mangan P.R., and Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr Opin Immunol 18 (2006) 349-356
10. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6 (2005) 1123-1132
11. Liu G., Wu Y., Gong S., and Zhao Y. Toll like receptors and graft rejection. Transpl Immunol 16 (2006) 25-31
12. Schnyder B., Schnyder-Candrian S., Pansky A., Schmitz M.L., Heim M., Ryffel B., et al. IL-17 reduces TNF-induced Rantes and VCAM-1 expression. Cytokine 31 (2005) 191-202
13. Asquith D.L., and McInnes I.B. Emerging cytokine targets in rheumatoid arthritis. Curr Opin Rheumatol 19 (2007) 246-251
14. Chen Y., Thai P., Zhao Y.H., Ho Y.S., DeSouza M.M., and Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 278 (2003) 17036-17043
15. Wong C.K., Ho C.Y., Li E.K., and Lam C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 9 (2000) 589-593
16. Yoshida S., Haque A., Mizobuchi T., Iwata T., Chiyo M., Webb T.J., et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and wellhealed lung transplants. Am J Transplant 6 (2006) 724-735
17. Ferretti S., Bonneau O., Dubois G.R., Jones C.E., and Trifilieff A. IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170 (2003) 2106-2112
18. Nakae S., Nambu A., Sudo K., and Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 171 (2003) 6173-6177
19. Tan W., Huang W., Zhong Q., and Schwarzenberger P. IL-17 receptor knockout mice have enhanced myelotoxicity and impaired hemopoietic recovery following gamma irradiation. J Immunol 176 (2006) 6186-6193
20. Doherty A.M. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 3 (1999) 466-473
21. Teixeira M.M., Gristwood R.W., Cooper N., and Hellewell P.G. Phosphodiesterase (PDE) 4 inhibitors: anti-inflammatory drugs of the future. Trends Pharmacol Sci 18 (1997) 164-171
22. Hoffmeister B., Kiecker F., Tesfa L., Volk H.D., Picker L.J., and Kern F. Mapping T cell epitopes by flow cytometry. Methods 292 (2003) 270-281
23. Fan Chung K. Phosphodiesterase inhibitors in airway diseases. Eur J Pharmacol 533 (2006) 110-117
24. Kwak H.J., Song J.S., Heo J.Y., Yang S.D., Nam J.Y., and Cheon H.G. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-κB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 315 (2005) 1188-1195
25. Hatzelmann A., and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 297 (2001) 267-279
26. Park H., Young Lee S., Lee D.S., and Yim M. Phosphodiesterase 4 inhibitor regulates the TRANCE/OPG ratio via COX-2 expression in a manner similar to PTH in osteoblasts. Biochem Biophys Res Commun 354 (2007) 178-183
27. Matusevicius D., Kivisäkk P., He B., Kostulas N., Ozenci V., Fredrikson S., et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5 (1999) 101-104
28. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 164 (2000) 2832-2838
29. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103 (1999) 1345-1352
30. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52 (2003) 65-70
31. Schwartz S., Beaulieu J.F., and Ruemmele F.M. Interleukin-17 is a potent immuno-modulator and regulator of normal human intestinal epithelial cell growth. Biochem Biophys Res Commun 337 (2005) 505-509
32. Inoue D., Numasaki M., Watanabe M., Kubo H., Sasaki T., Yasuda H., et al. IL-17A promotes the growth of airway epithelial cells through ERK-dependent signaling pathway. Biochem Biophys Res Commun 347 (2006) 852-858
33. Chen D., and Rothenberg E.V. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J Exp Med 179 (1994) 931-942
34. Jimenez J.L., Punzón C., Navarro J., Muñoz-Fernández M.A., and Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 299 (2001) 753-759
35. Kim K.W., Cho M.L., Park M.K., Yoon C.H., Park S.H., Lee S.H., et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 7 (2005) 139-148
36. Gruber T., Thuille N., Hermann-Kleiter N., Leitges M., and Baier G. Protein kinase Cepsilon is dispensable for TCR/CD3-signaling. Mol Immunol 42 (2005) 305-310
37. Doi T.S., Takahashi T., Taguchi O., Azuma T., and Obata Y. NF-kappa B RelA-deficient lymphocytes: normal development of T cells and B cells, impaired production of IgA and IgG1 and reduced proliferative responses. J Exp Med 185 (1997) 953-961